{"transactions":[{"id":678985,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-21T23:10:48.000Z","date":"2026-08-21","kind":"exercise","planned":false,"acquired":false,"shares":21055,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":94798,"derivative":{"exercise_price":0.72,"expiration_date":"2031-09-20","underlying":"Common Stock","underlying_shares":21055},"source":{"system":"sec-edgar","filing":"0001610717-26-000385","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000385/form4.xml","form_type":"4"}},{"id":678984,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-21T23:10:48.000Z","date":"2026-08-21","kind":"exercise","planned":false,"acquired":false,"shares":20553,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":88974,"derivative":{"exercise_price":0.72,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":20553},"source":{"system":"sec-edgar","filing":"0001610717-26-000385","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000385/form4.xml","form_type":"4"}},{"id":678983,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-21T23:10:48.000Z","date":"2026-08-20","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":200000,"derivative":{"exercise_price":1.52,"expiration_date":"2036-08-20","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001610717-26-000385","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000385/form4.xml","form_type":"4"}},{"id":678982,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-21T23:10:48.000Z","date":"2026-08-20","kind":"exercise","planned":false,"acquired":false,"shares":21685,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":115853,"derivative":{"exercise_price":0.72,"expiration_date":"2031-09-20","underlying":"Common Stock","underlying_shares":21685},"source":{"system":"sec-edgar","filing":"0001610717-26-000385","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000385/form4.xml","form_type":"4"}},{"id":678981,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-21T23:10:48.000Z","date":"2026-08-20","kind":"exercise","planned":false,"acquired":false,"shares":45026,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":0,"derivative":{"exercise_price":0.72,"expiration_date":"2033-01-19","underlying":"Common Stock","underlying_shares":45026},"source":{"system":"sec-edgar","filing":"0001610717-26-000385","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000385/form4.xml","form_type":"4"}},{"id":678980,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-21T23:10:48.000Z","date":"2026-08-20","kind":"exercise","planned":false,"acquired":false,"shares":67741,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":109527,"derivative":{"exercise_price":0.72,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":67741},"source":{"system":"sec-edgar","filing":"0001610717-26-000385","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000385/form4.xml","form_type":"4"}},{"id":678979,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-21T23:10:48.000Z","date":"2026-08-21","kind":"sale","planned":false,"acquired":false,"shares":21055,"price":1.5958,"value":33599.569,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6393, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001610717-26-000385","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000385/form4.xml","form_type":"4"}},{"id":678978,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-21T23:10:48.000Z","date":"2026-08-21","kind":"exercise","planned":false,"acquired":true,"shares":21055,"price":0.72,"value":15159.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":21055,"source":{"system":"sec-edgar","filing":"0001610717-26-000385","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000385/form4.xml","form_type":"4"}},{"id":678977,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-21T23:10:48.000Z","date":"2026-08-21","kind":"sale","planned":false,"acquired":false,"shares":20553,"price":1.5949,"value":32779.9797,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6379, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":48750,"source":{"system":"sec-edgar","filing":"0001610717-26-000385","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000385/form4.xml","form_type":"4"}},{"id":678976,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-21T23:10:48.000Z","date":"2026-08-21","kind":"exercise","planned":false,"acquired":true,"shares":20553,"price":0.72,"value":14798.16,"ownership":{"direct":true},"balance_after":69303,"source":{"system":"sec-edgar","filing":"0001610717-26-000385","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000385/form4.xml","form_type":"4"}},{"id":678975,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-21T23:10:48.000Z","date":"2026-08-20","kind":"sale","planned":false,"acquired":false,"shares":66711,"price":1.514,"value":101000.454,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $1.48 to $1.6252, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001610717-26-000385","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000385/form4.xml","form_type":"4"}},{"id":678974,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-21T23:10:48.000Z","date":"2026-08-20","kind":"exercise","planned":false,"acquired":true,"shares":45026,"price":0.72,"value":32418.72,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":66711,"source":{"system":"sec-edgar","filing":"0001610717-26-000385","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000385/form4.xml","form_type":"4"}},{"id":678973,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-21T23:10:48.000Z","date":"2026-08-20","kind":"exercise","planned":false,"acquired":true,"shares":21685,"price":0.72,"value":15613.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":21685,"source":{"system":"sec-edgar","filing":"0001610717-26-000385","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000385/form4.xml","form_type":"4"}},{"id":678972,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-21T23:10:48.000Z","date":"2026-08-20","kind":"sale","planned":false,"acquired":false,"shares":67741,"price":1.5144,"value":102586.9704,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $1.485 to $1.625, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":48750,"source":{"system":"sec-edgar","filing":"0001610717-26-000385","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000385/form4.xml","form_type":"4"}},{"id":678971,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-21T23:10:48.000Z","date":"2026-08-20","kind":"exercise","planned":false,"acquired":true,"shares":67741,"price":0.72,"value":48773.52,"ownership":{"direct":true},"balance_after":116491,"source":{"system":"sec-edgar","filing":"0001610717-26-000385","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000385/form4.xml","form_type":"4"}},{"id":681644,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-19","kind":"exercise","planned":false,"acquired":false,"shares":30918,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":45026,"derivative":{"exercise_price":0.72,"expiration_date":"2033-01-19","underlying":"Common Stock","underlying_shares":30918},"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681643,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-19","kind":"exercise","planned":false,"acquired":false,"shares":17732,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":177268,"derivative":{"exercise_price":0.72,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":17732},"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681642,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-19","kind":"exercise","planned":false,"acquired":false,"shares":13268,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":23367,"derivative":{"exercise_price":0.72,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":13268},"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681641,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-18","kind":"exercise","planned":false,"acquired":false,"shares":34987,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":75944,"derivative":{"exercise_price":0.72,"expiration_date":"2033-01-19","underlying":"Common Stock","underlying_shares":34987},"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681640,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-18","kind":"exercise","planned":false,"acquired":false,"shares":34162,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":36635,"derivative":{"exercise_price":0.72,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":34162},"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681639,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-17","kind":"exercise","planned":false,"acquired":false,"shares":29737,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":0,"derivative":{"exercise_price":0.72,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":29737},"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681638,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-17","kind":"exercise","planned":false,"acquired":false,"shares":25279,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":110931,"derivative":{"exercise_price":0.72,"expiration_date":"2033-01-19","underlying":"Common Stock","underlying_shares":25279},"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681637,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-17","kind":"exercise","planned":false,"acquired":false,"shares":1,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":999999,"derivative":{"exercise_price":0.72,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":1},"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681636,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-17","kind":"exercise","planned":false,"acquired":false,"shares":1424,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":70797,"derivative":{"exercise_price":0.72,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":1424},"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681635,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-17","kind":"exercise","planned":false,"acquired":false,"shares":15355,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":192546,"derivative":{"exercise_price":0.72,"expiration_date":"2033-01-19","underlying":"Common Stock","underlying_shares":15355},"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681634,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-17","kind":"exercise","planned":false,"acquired":false,"shares":40890,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.72,"expiration_date":"2031-09-20","underlying":"Common Stock","underlying_shares":40890},"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681633,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":30918,"price":1.6459,"value":50887.9362,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"This transaction was executed in multiple trades at prices ranging from $1.62 to $1.7006, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681632,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-19","kind":"exercise","planned":false,"acquired":true,"shares":30918,"price":0.72,"value":22260.96,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":30918,"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681631,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":31000,"price":1.6461,"value":51029.1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"This transaction was executed in multiple trades at prices ranging from $1.62 to $1.6995, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":48750,"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681630,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-19","kind":"exercise","planned":false,"acquired":true,"shares":17732,"price":0.72,"value":12767.04,"ownership":{"direct":true},"balance_after":79750,"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681629,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-19","kind":"exercise","planned":false,"acquired":true,"shares":13268,"price":0.72,"value":9552.96,"ownership":{"direct":true},"balance_after":62018,"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681628,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":34987,"price":1.5859,"value":55485.8833,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"This transaction was executed in multiple trades at prices ranging from $1.48 to $1.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681627,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-18","kind":"exercise","planned":false,"acquired":true,"shares":34987,"price":0.72,"value":25190.64,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":34987,"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681626,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":34162,"price":1.5847,"value":54136.5214,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"This transaction was executed in multiple trades at prices ranging from $1.49 to $1.645, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":48750,"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681625,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-18","kind":"exercise","planned":false,"acquired":true,"shares":34162,"price":0.72,"value":24596.64,"ownership":{"direct":true},"balance_after":82912,"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681624,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-17","kind":"sale","planned":false,"acquired":false,"shares":55016,"price":1.5047,"value":82782.5752,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $1.46 to $1.555, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681623,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-17","kind":"exercise","planned":false,"acquired":true,"shares":29737,"price":0.72,"value":21410.64,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":55016,"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681622,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-17","kind":"exercise","planned":false,"acquired":true,"shares":25279,"price":0.72,"value":18200.88,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":25279,"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681621,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-17","kind":"sale","planned":false,"acquired":false,"shares":34020,"price":1.4853,"value":50529.906,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $1.46 to $1.5277, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":48750,"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681620,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-17","kind":"sale","planned":false,"acquired":false,"shares":57670,"price":1.5055,"value":86822.185,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $1.46 to $1.555, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":82770,"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681619,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-17","kind":"exercise","planned":false,"acquired":true,"shares":1,"price":0.72,"value":0.72,"ownership":{"direct":true},"balance_after":140440,"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681618,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-17","kind":"exercise","planned":false,"acquired":true,"shares":1424,"price":0.72,"value":1025.28,"ownership":{"direct":true},"balance_after":140439,"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681617,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-17","kind":"exercise","planned":false,"acquired":true,"shares":15355,"price":0.72,"value":11055.6,"ownership":{"direct":true},"balance_after":139015,"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":681616,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-19T23:17:14.000Z","date":"2026-08-17","kind":"exercise","planned":false,"acquired":true,"shares":40890,"price":0.72,"value":29440.8,"ownership":{"direct":true},"balance_after":123660,"source":{"system":"sec-edgar","filing":"0001610717-26-000362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000362/form4.xml","form_type":"4"}},{"id":893632,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-19T22:07:13.000Z","date":"2026-02-17","kind":"sale","planned":false,"acquired":false,"shares":6165,"price":3.555,"value":21916.575,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":82770,"source":{"system":"sec-edgar","filing":"0001610717-26-000054","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000054/form4.xml","form_type":"4"}},{"id":942310,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-09T21:19:28.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the first anniversary measured from January 8, 2026 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":750000,"derivative":{"exercise_price":2.33,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001610717-26-000011","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000011/form4.xml","form_type":"4"}},{"id":1000434,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-13T21:39:15.000Z","date":"2025-11-11","kind":"sale","planned":true,"acquired":false,"shares":114703,"price":2.6767,"value":307025.5201,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 22, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades in prices ranging from $2.65 to $2.81, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Aurora Family Trust."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001610717-25-000378","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071725000378/form4.xml","form_type":"4"}},{"id":1129452,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option  (Right to Buy)","published_at":"2025-05-30T22:30:45.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held\nby members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August\n13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the \"Vesting Commencement Date\"), and 1/48th of the\ntotal number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of\nthe Vesting Commencement Date"}],"balance_after":1000000,"derivative":{"exercise_price":0.72,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000950170-25-079922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079922/ownership.xml","form_type":"4"}},{"id":1129451,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:45.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":195000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held\nby members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August\n13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":195000,"derivative":{"exercise_price":0.72,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0000950170-25-079922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079922/ownership.xml","form_type":"4"}},{"id":1129450,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:45.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":29737,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held\nby members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August\n13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":29737,"derivative":{"exercise_price":0.72,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":29737},"source":{"system":"sec-edgar","filing":"0000950170-25-079922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079922/ownership.xml","form_type":"4"}},{"id":1129449,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:45.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":72221,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held\nby members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August\n13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":72221,"derivative":{"exercise_price":0.72,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":72221},"source":{"system":"sec-edgar","filing":"0000950170-25-079922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079922/ownership.xml","form_type":"4"}},{"id":1129448,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:45.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":136210,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held\nby members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August\n13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":136210,"derivative":{"exercise_price":0.72,"expiration_date":"2033-01-19","underlying":"Common Stock","underlying_shares":136210},"source":{"system":"sec-edgar","filing":"0000950170-25-079922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079922/ownership.xml","form_type":"4"}},{"id":1129447,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:45.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":207901,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held\nby members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August\n13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":207901,"derivative":{"exercise_price":0.72,"expiration_date":"2033-01-19","underlying":"Common Stock","underlying_shares":207901},"source":{"system":"sec-edgar","filing":"0000950170-25-079922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079922/ownership.xml","form_type":"4"}},{"id":1129446,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:45.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":137538,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held\nby members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August\n13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":137538,"derivative":{"exercise_price":0.72,"expiration_date":"2031-09-20","underlying":"Common Stock","underlying_shares":137538},"source":{"system":"sec-edgar","filing":"0000950170-25-079922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079922/ownership.xml","form_type":"4"}},{"id":1129445,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:45.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":40890,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held\nby members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August\n13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the first anniversary measured from August 2, 2021 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":40890,"derivative":{"exercise_price":0.72,"expiration_date":"2031-09-20","underlying":"Common Stock","underlying_shares":40890},"source":{"system":"sec-edgar","filing":"0000950170-25-079922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079922/ownership.xml","form_type":"4"}},{"id":1129444,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option  (Right to Buy)","published_at":"2025-05-30T22:30:45.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the \"Vesting Commencement Date\"), and 1/48th of the\ntotal number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of\nthe Vesting Commencement Date"}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2035-02-13","underlying":"Common  Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000950170-25-079922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079922/ownership.xml","form_type":"4"}},{"id":1129443,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:45.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":195000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0000950170-25-079922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079922/ownership.xml","form_type":"4"}},{"id":1129442,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:45.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":29737,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":29737},"source":{"system":"sec-edgar","filing":"0000950170-25-079922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079922/ownership.xml","form_type":"4"}},{"id":1129441,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:45.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":72221,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":72221},"source":{"system":"sec-edgar","filing":"0000950170-25-079922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079922/ownership.xml","form_type":"4"}},{"id":1129440,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:45.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":136210,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2033-01-19","underlying":"Common Stock","underlying_shares":136210},"source":{"system":"sec-edgar","filing":"0000950170-25-079922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079922/ownership.xml","form_type":"4"}},{"id":1129439,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:45.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":207901,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2033-01-19","underlying":"Common Stock","underlying_shares":207901},"source":{"system":"sec-edgar","filing":"0000950170-25-079922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079922/ownership.xml","form_type":"4"}},{"id":1129438,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:45.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":137538,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2031-09-20","underlying":"Common Stock","underlying_shares":137538},"source":{"system":"sec-edgar","filing":"0000950170-25-079922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079922/ownership.xml","form_type":"4"}},{"id":1129437,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:45.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40890,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the first anniversary measured from August 2, 2021 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2031-09-20","underlying":"Common Stock","underlying_shares":40890},"source":{"system":"sec-edgar","filing":"0000950170-25-079922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079922/ownership.xml","form_type":"4"}},{"id":1256140,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2025-02-20T22:13:14.000Z","date":"2025-02-18","kind":"sale","planned":true,"acquired":false,"shares":8565,"price":1.6751,"value":14347.2315,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 22, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades in prices ranging from $1.66 to $1.705, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":88935,"source":{"system":"sec-edgar","filing":"0001610717-25-000029","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071725000029/form4.xml","form_type":"4"}},{"id":1264125,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:07.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":195000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":195000,"derivative":{"exercise_price":1.69,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0000950170-25-022320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022320/ownership.xml","form_type":"4"}},{"id":1264124,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:07.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":29737,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":29737,"derivative":{"exercise_price":1.69,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":29737},"source":{"system":"sec-edgar","filing":"0000950170-25-022320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022320/ownership.xml","form_type":"4"}},{"id":1264123,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:07.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":72221,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":72221,"derivative":{"exercise_price":1.69,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":72221},"source":{"system":"sec-edgar","filing":"0000950170-25-022320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022320/ownership.xml","form_type":"4"}},{"id":1264122,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:07.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":136210,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":136210,"derivative":{"exercise_price":1.69,"expiration_date":"2033-01-19","underlying":"Common Stock","underlying_shares":136210},"source":{"system":"sec-edgar","filing":"0000950170-25-022320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022320/ownership.xml","form_type":"4"}},{"id":1264121,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:07.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":207901,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":207901,"derivative":{"exercise_price":1.69,"expiration_date":"2033-01-19","underlying":"Common Stock","underlying_shares":207901},"source":{"system":"sec-edgar","filing":"0000950170-25-022320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022320/ownership.xml","form_type":"4"}},{"id":1264120,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:07.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":137538,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":137538,"derivative":{"exercise_price":1.69,"expiration_date":"2031-09-20","underlying":"Common Stock","underlying_shares":137538},"source":{"system":"sec-edgar","filing":"0000950170-25-022320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022320/ownership.xml","form_type":"4"}},{"id":1264119,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:07.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":40890,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on the first anniversary measured from August 2, 2021 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":40890,"derivative":{"exercise_price":1.69,"expiration_date":"2031-09-20","underlying":"Common Stock","underlying_shares":40890},"source":{"system":"sec-edgar","filing":"0000950170-25-022320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022320/ownership.xml","form_type":"4"}},{"id":1264118,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:07.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":195000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":18.07,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0000950170-25-022320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022320/ownership.xml","form_type":"4"}},{"id":1264117,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:07.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":29737,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":0,"derivative":{"exercise_price":6.36,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":29737},"source":{"system":"sec-edgar","filing":"0000950170-25-022320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022320/ownership.xml","form_type":"4"}},{"id":1264116,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:07.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":72221,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":6.36,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":72221},"source":{"system":"sec-edgar","filing":"0000950170-25-022320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022320/ownership.xml","form_type":"4"}},{"id":1264115,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:07.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":136210,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":0,"derivative":{"exercise_price":6.51,"expiration_date":"2033-01-19","underlying":"Common Stock","underlying_shares":136210},"source":{"system":"sec-edgar","filing":"0000950170-25-022320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022320/ownership.xml","form_type":"4"}},{"id":1264114,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:07.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":207901,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":6.51,"expiration_date":"2033-01-19","underlying":"Common Stock","underlying_shares":207901},"source":{"system":"sec-edgar","filing":"0000950170-25-022320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022320/ownership.xml","form_type":"4"}},{"id":1264113,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:07.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":137538,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":0,"derivative":{"exercise_price":4.24,"expiration_date":"2031-09-20","underlying":"Common Stock","underlying_shares":137538},"source":{"system":"sec-edgar","filing":"0000950170-25-022320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022320/ownership.xml","form_type":"4"}},{"id":1264112,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:07.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40890,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on the first anniversary measured from August 2, 2021 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":4.24,"expiration_date":"2031-09-20","underlying":"Common Stock","underlying_shares":40890},"source":{"system":"sec-edgar","filing":"0000950170-25-022320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022320/ownership.xml","form_type":"4"}},{"id":1264111,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:07.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":1000000,"derivative":{"exercise_price":1.69,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000950170-25-022320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022320/ownership.xml","form_type":"4"}},{"id":1407833,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-13T21:22:10.000Z","date":"2024-09-12","kind":"gift","planned":false,"acquired":true,"shares":29737,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Aurora Family Trust."}],"balance_after":29737,"derivative":{"exercise_price":6.36,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":29737},"source":{"system":"sec-edgar","filing":"0001610717-24-000475","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000475/form4.xml","form_type":"4"}},{"id":1407832,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-13T21:22:10.000Z","date":"2024-09-12","kind":"gift","planned":false,"acquired":false,"shares":29737,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":72221,"derivative":{"exercise_price":6.36,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":29737},"source":{"system":"sec-edgar","filing":"0001610717-24-000475","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000475/form4.xml","form_type":"4"}},{"id":1407831,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-13T21:22:10.000Z","date":"2024-09-12","kind":"gift","planned":false,"acquired":true,"shares":136210,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Aurora Family Trust."}],"balance_after":136210,"derivative":{"exercise_price":6.51,"expiration_date":"2033-01-18","underlying":"Common Stock","underlying_shares":136210},"source":{"system":"sec-edgar","filing":"0001610717-24-000475","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000475/form4.xml","form_type":"4"}},{"id":1407830,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-13T21:22:10.000Z","date":"2024-09-12","kind":"gift","planned":false,"acquired":false,"shares":136210,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":207901,"derivative":{"exercise_price":6.51,"expiration_date":"2033-01-18","underlying":"Common Stock","underlying_shares":136210},"source":{"system":"sec-edgar","filing":"0001610717-24-000475","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000475/form4.xml","form_type":"4"}},{"id":1407829,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-13T21:22:10.000Z","date":"2024-09-12","kind":"gift","planned":false,"acquired":true,"shares":137538,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Aurora Family Trust."}],"balance_after":137538,"derivative":{"exercise_price":4.24,"expiration_date":"2031-09-20","underlying":"Common Stock","underlying_shares":137538},"source":{"system":"sec-edgar","filing":"0001610717-24-000475","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000475/form4.xml","form_type":"4"}},{"id":1407828,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-13T21:22:10.000Z","date":"2024-09-12","kind":"gift","planned":false,"acquired":false,"shares":137538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"25% of the shares subject to the option vest on the first anniversary measured from August 2, 2021 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":40890,"derivative":{"exercise_price":4.24,"expiration_date":"2031-09-20","underlying":"Common Stock","underlying_shares":137538},"source":{"system":"sec-edgar","filing":"0001610717-24-000475","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000475/form4.xml","form_type":"4"}},{"id":1536279,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2024-04-24T21:00:31.000Z","date":"2024-04-22","kind":"gift","planned":false,"acquired":false,"shares":114703,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 22, 2024, the Reporting Person transferred, for no consideration, 114,703 shares of Common Stock to Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries."}],"balance_after":97500,"source":{"system":"sec-edgar","filing":"0001610717-24-000222","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000222/form4.xml","form_type":"4"}},{"id":1638608,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-16T21:20:29.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":195000,"derivative":{"exercise_price":18.07,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0001610717-24-000068","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000068/form4.xml","form_type":"4"}},{"id":1638607,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2024-02-16T21:20:29.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":97500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the \"Vesting Commencement Date\"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":212203,"source":{"system":"sec-edgar","filing":"0001610717-24-000068","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000068/form4.xml","form_type":"4"}},{"id":3252181,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Affairs Off"}}],"security":"Restricted Stock Unit","published_at":"2020-02-24T19:32:38.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-20-001623","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218020001623/primarydocument.xml","form_type":"4"}},{"id":3252180,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Affairs Off"}}],"security":"Restricted Stock Unit","published_at":"2020-02-24T19:32:38.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-20-001623","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218020001623/primarydocument.xml","form_type":"4"}},{"id":3252179,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Affairs Off"}}],"security":"Restricted Stock Unit","published_at":"2020-02-24T19:32:38.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":22500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001562180-20-001623","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218020001623/primarydocument.xml","form_type":"4"}},{"id":3252178,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Affairs Off"}}],"security":"Restricted Stock Unit","published_at":"2020-02-24T19:32:38.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":708,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":708},"source":{"system":"sec-edgar","filing":"0001562180-20-001623","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218020001623/primarydocument.xml","form_type":"4"}},{"id":3252177,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Affairs Off"}}],"security":"Restricted Stock Unit","published_at":"2020-02-24T19:32:38.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":2814,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2814},"source":{"system":"sec-edgar","filing":"0001562180-20-001623","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218020001623/primarydocument.xml","form_type":"4"}},{"id":3252176,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Affairs Off"}}],"security":"Restricted Stock Unit","published_at":"2020-02-24T19:32:38.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":574,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":574},"source":{"system":"sec-edgar","filing":"0001562180-20-001623","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218020001623/primarydocument.xml","form_type":"4"}},{"id":3252175,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Affairs Off"}}],"security":"Restricted Stock Unit","published_at":"2020-02-24T19:32:38.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":6250,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001562180-20-001623","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218020001623/primarydocument.xml","form_type":"4"}},{"id":3252174,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Affairs Off"}}],"security":"Employee Stock Options (Right to buy)","published_at":"2020-02-24T19:32:38.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":28000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":8.05,"expiration_date":"2029-11-10","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001562180-20-001623","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218020001623/primarydocument.xml","form_type":"4"}},{"id":3252173,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Affairs Off"}}],"security":"Employee Stock Options (Right to buy)","published_at":"2020-02-24T19:32:38.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":6.97,"expiration_date":"2028-02-10","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001562180-20-001623","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218020001623/primarydocument.xml","form_type":"4"}},{"id":3252172,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Affairs Off"}}],"security":"Employee Stock Options (Right to buy)","published_at":"2020-02-24T19:32:38.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":7040,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":28.25,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":7040},"source":{"system":"sec-edgar","filing":"0001562180-20-001623","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218020001623/primarydocument.xml","form_type":"4"}},{"id":3252171,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Affairs Off"}}],"security":"Employee Stock Options (Right to buy)","published_at":"2020-02-24T19:32:38.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":28130,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":28.25,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":28130},"source":{"system":"sec-edgar","filing":"0001562180-20-001623","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218020001623/primarydocument.xml","form_type":"4"}},{"id":3252170,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":20891,"kind":"person","name":"Aurora Daljit Singh","position":1,"cik":"0001793971","reported_name":"Aurora Daljit Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Affairs Off"}}],"security":"Employee Stock Options (Right to buy)","published_at":"2020-02-24T19:32:38.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":11500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":33.84,"expiration_date":"2027-02-16","underlying":"Common Stock","underlying_shares":11500},"source":{"system":"sec-edgar","filing":"0001562180-20-001623","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218020001623/primarydocument.xml","form_type":"4"}}],"next_cursor":"2020-02-24T19:32:38.000000Z,3252170"}